Table 4

Association of baseline SUA level and incident dementia: sensitivity analysis in participants not taking NSAIDs (n=1348)

	%	Model 1*		Model 2†		Model 3‡		Model 4§
SUA level (μmol/L)	(N event)	HR (95% CI)^†	p	HR (95% CI)^†	p	HR (95% CI)^†	p	HR (95% CI)^†	p
All-cause dementia (n=93)
<75th percentile	5.7 (57)	1.00 (ref.)		1.00 (ref.)		1.00 (ref.)		1.00 (ref.)
≥75th percentile	10.5 (36)	1.68 (1.10; 2.57)	0.016	1.89 (1.18; 3.02)	0.008	1.83 (1.14; 2.93)	0.013	1.93 (1.20; 3.12)	0.007
Q1	4.6 (16)	1.00 (ref.)		1.00 (ref.)		1.00 (ref.)		1.00 (ref.)
Q2	5.8 (20)	1.09 (0.56; 2.11)	0.80	1.16 (0.59; 2.28)	0.66	1.19 (0.61; 2.34)	0.61	1.31 (0.66; 2.58)	0.44
Q3	6.6 (21)	1.37 (0.72; 2.63)	0.34	1.56 (0.80; 3.04)	0.19	1.58 (0.81; 3.09)	0.18	1.78 (0.9; 3.5)	0.10
Q4	10.5 (36)	1.93 (1.07; 3.49)	0.03	2.37 (1.23; 4.55)	0.01	2.32 (1.20; 4.46)	0.012	2.63 (1.36; 5.09)	0.004
p for linear trend			0.011		0.004		0.005		0.002
Alzheimer’s disease (n=62)
< 75th percentile	4.0 (39)	1.00 (ref.)		1.00 (ref.)		1.00 (ref.)		1.00 (ref.)
≥75th percentile	6.9 (23)	1.56 (0.92; 2.64)	0.10	1.83 (1.02; 3.27)	0.041	1.77 (0.99; 3.19)	0.06	1.87 (1.03; 3.37)	0.038
Q1	3.5 (12)	1.00 (ref.)		1.00 (ref.)		1.00 (ref.)		1.00 (ref.)
Q2	3.6 (12)	0.87 (0.39; 1.94)	0.73	0.92 (0.40; 2.08)	0.83	0.94 (0.41; 2.14)	0.88	1.04 (0.45; 2.39)	0.92
Q3	4.8 (15)	1.30 (0.61; 2.77)	0.50	1.48 (0.68; 3.23)	0.33	1.51 (0.69; 3.30)	0.31	1.70 (0.77; 3.79)	0.19
Q4	6.9 (23)	1.63 (0.80; 3.30)	0.18	2.06 (0.95; 4.50)	0.07	2.03 (0.93; 4.44)	0.08	2.31 (1.05; 5.08)	0.037
p for linear trend			0.08		0.026		0.033		0.016
Vascular or mixed dementia (n=18)
<75th percentile	0.9 (9)	1.00 (ref.)		1.00 (ref.)		1.00 (ref.)		1.00 (ref.)
≥75th percentile	2.8 (9)	2.51 (0.99; 6.33)	0.05	2.02 (0.65; 6.26)	0.22	1.82 (0.57; 5.78)	0.31	1.72 (0.55; 5.41)	0.35
Q1	0.6 (2)	1.00 (ref.)		1.00 (ref.)		1.00 (ref.)		1.00 (ref.)
Q2	1.5 (5)	1.87 (0.36; 9.70)	0.46	2.29 (0.42; 12.42)	0.34	2.57 (0.47; 14.18)	0.28	2.35 (0.43; 12.95)	0.33
Q3	0.7 (2)	1.00 (0.14; 7.10)	0.99	1.25 (0.16; 9.45)	0.83	1.32 (0.17; 10.10)	0.79	1.25 (0.16; 9.70)	0.83
Q4	2.8 (9)	3.38 (0.73; 15.73)	0.12	3.22 (0.56; 18.62)	0.19	3.07 (0.52; 18.10)	0.22	2.73 (0.47; 16.04)	0.27
p for linear trend			0.08		0.23		0.29		0.34

*Model 1: adjusted for education level, gender.
†Model 2: model 1 + BMI. tobacco and alcohol consumption, cholesterol (LDL and HDL), triglycerides, diabetes mellitus, hypertension, interaction between hypertension and time (age at last follow-up or dementia occurrence), history of cardiovascular disease, glomerular filtration rate and APOE-ε4.
‡Model 3: model 2 + aspirin or diuretics.
§Model 4: model 3 + CRP, IL-6 levels and interaction between IL-6 and time (age at last follow-up or dementia occurrence).
Q1: quartile 1 (lowest quartile); Q1: <260 in men, <209 for women; Q2: 260–299 for men, 209–247 for women; Q3: 299–345 for men, 247–292 for women; Q4: ≥345 for men, ≥292 for women.
APOE, apolipoprotein E; BMI, body mass index; CRP, C reactive protein; HDL, high-density lipoprotein; IL, interleukin; LDL, low-density lipoprotein; NSAIDs, non-steroidal anti-inflammatory drugs; SUA, serum uric acid.